Pathology

Additonal guidance on the histopathologic requirments for FOxTROT can be found below:

 

The following documents provide futher information relating to tumour grading:

  1. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P. Cancer. 2002 Feb 15;94(4):1121-30 
  2. Pathological features of rectal cancer after preoperative radiochemotherapy. Dworak O, Keilholz L, Hoffmann A. Int J Colorectal Dis. 1997;12(1):19-23
  3. Histologic response grading after chemoradiation in locally advanced rectal cancer: a proposal for standardized reporting. Glynne-Jones R, Anyemene N. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):971-3
  4. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, et al. Cancer. 1994 Jun 1;73(11):2680-6
  5. Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system. Wheeler JM, Warren BF, Mortensen NJ, Ekanyaka N, Kulacoglu H, Jones AC, George BD, Kettlewell MG. Dis Colon Rectum. 2002 Aug;45(8):1051-6
  6. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C. J Clin Oncol. 2005 Dec 1;23(34):8688-96

If you have any queries relating to the histopathologic requirments for FOxTROT please contact the FOxTROT Trial office to register your interest and for further information:

Email:  foxtrot-trial@contacts.bham.ac.uk

Tel:      0121 415 9105

Fax:     0121 415 8871

 

 FOxTROT Logo

FOxTROT

EudraCT Number: 2007-001987-55
REC West Glasgow: 07/S0703/57
ISRCTN87163246

 

FOxTROT Protocol v6.0 (09/07/12)

 

Contact the FOxTROT Team